UBS Group
NVO

UBS Group’s Novo Nordisk NVO Stock Holding History

UBS Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$191M Sell
3,984,940
-580,768
-13% -$25M 0.02% 694
2026
Q1 		$168M Sell
4,565,708
-346,183
-7% -$16.4M 0.03% 703
2025
Q4 		$250M Buy
4,911,891
+1,221,675
+33% +$62.5M 0.04% 469
2025
Q3 		$205M Buy
3,690,216
+1,833,169
+99% +$107M 0.03% 573
2025
Q2 		$128M Buy
1,857,047
+424,021
+30% +$28.8M 0.02% 796
2025
Q1 		$99.5M Sell
1,433,026
-43,612
-3% -$3.6M 0.02% 935
2024
Q4 		$127M Buy
1,476,638
+518,914
+54% +$56.1M 0.02% 759
2024
Q3 		$114M Buy
957,724
+43,525
+5% +$5.8M 0.02% 663
2024
Q2 		$130M Buy
914,199
+148,546
+19% +$19.7M 0.03% 515
2024
Q1 		$98.3M Buy
765,653
+213,486
+39% +$25.4M 0.02% 655
2023
Q4 		$57.1M Sell
552,167
-75,223
-12% -$7.44M 0.02% 904
2023
Q3 		$57.1M Buy
627,390
+143,960
+30% +$12.7M 0.02% 764
2023
Q2 		$39.1M Sell
483,430
-56,016
-10% -$4.58M 0.01% 963
2023
Q1 		$42.9M Sell
539,446
-44,742
-8% -$3.17M 0.02% 862
2022
Q4 		$39.5M Sell
584,188
-10,954
-2% -$642K 0.01% 943
2022
Q3 		$29.6M Buy
595,142
+87,696
+17% +$4.7M 0.01% 1010
2022
Q2 		$28.3M Sell
507,446
-129,622
-20% -$7.19M 0.01% 1098
2022
Q1 		$35.4M Sell
637,068
-29,596
-4% -$1.52M 0.01% 1056
2021
Q4 		$37.3M Buy
666,664
+9,616
+1% +$521K 0.01% 1143
2021
Q3 		$31.5M Sell
657,048
-23,584
-3% -$1.14M 0.01% 1140
2021
Q2 		$28.5M Sell
680,632
-214,836
-24% -$8.33M 0.01% 1219
2021
Q1 		$30.2M Buy
895,468
+6,414
+0.7% +$228K 0.01% 1156
2020
Q4 		$31M Sell
889,054
-39,510
-4% -$1.37M 0.01% 1065
2020
Q3 		$32.2M Buy
928,564
+4,598
+0.5% +$153K 0.01% 881
2020
Q2 		$30.3M Buy
923,966
+72,984
+9% +$2.33M 0.01% 842
2020
Q1 		$25.6M Sell
850,982
-28,442
-3% -$847K 0.01% 859
2019
Q4 		$25.4M Sell
879,424
-3,456
-0.4% -$95.7K 0.01% 1207
2019
Q3 		$22.8M Sell
882,880
-481,876
-35% -$12.2M 0.01% 1145
2019
Q2 		$34.8M Buy
1,364,756
+258,086
+23% +$6.38M 0.01% 867
2019
Q1 		$28.9M Sell
1,106,670
-32,464
-3% -$798K 0.01% 922
2018
Q4 		$26.2M Sell
1,139,134
-71,780
-6% -$1.6M 0.01% 908
2018
Q3 		$28.5M Buy
1,210,914
+83,358
+7% +$2.03M 0.01% 971
2018
Q2 		$26M Sell
1,127,556
-145,078
-11% -$3.45M 0.01% 1009
2018
Q1 		$31.3M Sell
1,272,634
-152,990
-11% -$4.02M 0.01% 872
2017
Q4 		$38.3M Buy
1,425,624
+155,580
+12% +$3.96M 0.02% 802
2017
Q3 		$30.6M Buy
1,270,044
+7,286
+0.6% +$165K 0.01% 865
2017
Q2 		$27.1M Buy
1,262,758
+127,854
+11% +$2.58M 0.01% 866
2017
Q1 		$19.5M Buy
1,134,904
+338,186
+42% +$5.89M 0.01% 1047
2016
Q4 		$14.3M Sell
796,718
-1,990
-0.2% -$36.1K 0.01% 1249
2016
Q3 		$16.6M Sell
798,708
-18,988
-2% -$471K 0.01% 1090
2016
Q2 		$22M Sell
817,696
-25,802
-3% -$708K 0.01% 888
2016
Q1 		$22.9M Sell
843,498
-182,928
-18% -$4.9M 0.02% 804
2015
Q4 		$29.8M Buy
1,026,426
+44,284
+5% +$1.23M 0.02% 740
2015
Q3 		$26.6M Buy
982,142
+134,544
+16% +$3.81M 0.02% 736
2015
Q2 		$23.2M Sell
847,598
-62,556
-7% -$1.76M 0.02% 880
2015
Q1 		$24.3M Sell
910,154
-140,952
-13% -$3.25M 0.02% 851
2014
Q4 		$22.2M Buy
+1,051,106
New +$23.5M 0.02% 920

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

UBS Group's NVO Position: Q2 2026 in Review

UBS Group reduced its Novo Nordisk (NVO) stake by 13% in Q2 2026, selling an estimated $25M and leaving 3,984,940 shares worth $191M. The position accounts for 0.02% of the portfolio, ranked #694.

UBS Group first reported a position in NVO in Q4 2014 and has held it in 47 quarters since. The position peaked at $250M in Q4 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • UBS Group held 3,984,940 shares of Novo Nordisk worth $191M as of Q2 2026.
  • UBS Group sold 580,768 Novo Nordisk shares in Q2 2026, an estimated $25M.
  • Novo Nordisk made up 0.02% of UBS Group's portfolio in Q2 2026, its #694 holding.
  • UBS Group first reported a position in Novo Nordisk in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Novo Nordisk position peaked at $250M in Q4 2025.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.